-
BETHLEHEM, Pa., Nov. 03, 2022 (GLOBE NEWSWIRE) -- OraSure Technologies, Inc. (NASDAQ: OSUR), a global leader in point-of-care and homediagnostic testing and sample collection technologies, announced today that the Company received U.S. FDA clearance for its ORAcollect®•Dx salivacollection device for OTC (i.e. direct-to-consumer) use. The device had been previously cleared for prescription use by the FDA...
-
OraSure Technologies Launches New Product for Microbiome Researchers to Study DNA and RNA
BETHLEHEM, Pa., July 14, 2022 (GLOBE NEWSWIRE) -- OraSure Technologies, Inc. (NASDAQ: OSUR), a global leader in point-of-care and home diagnostic testing and sample collection technologies, announced today that its OMNIgene ® •GUT DNA and RNA product ( OMR-205 ) is now available to gut microbiome...
-
BETHLEHEM, Pa., April 07, 2022 (GLOBE NEWSWIRE) -- OraSure Technologies, Inc. (NASDAQ: OSUR), a global leader in point-of-care and home diagnostic testing and sample collection technologies, announced today its OMNIgene®·GUT Dx (OMD-200) microbiome collection device, has been granted de novo authorization from the U.S. Food and Drug Administration (FDA) and the Company is commercially launching the device.
-
BETHLEHEM, Pa., March 31, 2022 (GLOBE NEWSWIRE) - OraSure Technologies, Inc. (NASDAQ: OSUR), a global leader in point-of-care and home diagnostic testing and sample collection technologies, announced today that its’ Diversigen subsidiary has launched a new service to provide metatranscriptomic sequencing and analysis of gut microbiome samples.
Press Releases
2022
Nov 03
Jul 14
Apr 07
Mar 31